Astellas Pharma Inc. is divesting a portfolio of 16 of its older drugs in Japan, in the latest in a string of similar moves by innovative pharma firms in the country to move out of low-margin products amid rising price pressures and generic competition.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?